Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced the launch of a new sub-brand, RenBiologics?, to represent the company?s antibody discovery business division. RenBiologics business will cover out-licensing/co-development of the company?s extensive library of fully human antibodies, as well as licensing of RenMice®, the company?s fully human antibody/TCR discovery platforms. The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company?s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Equities
2315
CNE100005D27
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.49 CNY | -7.19% | -6.72% | -37.48% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.48% | 383M | |
+38.66% | 52.85B | |
+35.11% | 38.24B | |
-7.81% | 38.87B | |
-10.77% | 26.79B | |
+11.77% | 26.16B | |
-17.82% | 19.9B | |
+35.09% | 13.18B | |
+29.17% | 12.24B | |
-3.05% | 11.79B |
- Stock Market
- Equities
- 2315 Stock
- News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics